Search

Your search keyword '"Statnick, Michael A"' showing total 201 results

Search Constraints

Start Over You searched for: Author "Statnick, Michael A" Remove constraint Author: "Statnick, Michael A"
201 results on '"Statnick, Michael A"'

Search Results

1. Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction.

7. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

9. Regulation of Endogenous (Male) Rodent GLP-1 Secretion and Human Islet Insulin Secretion by Antagonism of Somatostatin Receptor 5

10. A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models

12. Activation of mesolimbic dopamine neurons during novel and daily limited access to palatable food is blocked by the opioid antagonist LY255582

16. Antagonism of opioid receptors reduces body fat in obese rats by decreasing food intake and stimulating lipid utilization

19. Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery

27. The current state of GPCR‐based drug discovery to treat metabolic disease

31. Preclinical findings predicting efficacy and side‐effect profile of LY 2940094, an antagonist of nociceptin receptors

32. An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis

34. Erratum: A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies

36. A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies

37. Determining Pharmacological Selectivity of the Kappa Opioid Receptor Antagonist LY2456302 Using Pupillometry as a Translational Biomarker in Rat and Human

39. Discovery of a Novel Series of Orally Active Nociceptin/Orphanin FQ (NOP) Receptor Antagonists Based on a Dihydrospiro(piperidine-4,7′-thieno[2,3-c]pyran) Scaffold

40. A novel nociceptin‐1 receptor antagonist produces antidepressant‐ and anxiolytic‐related effects in rodents (656.3)

41. A novel nociceptin receptor antagonist inhibits feeding behavior in rodents (656.1)

43. A novel, potent, orally‐bioavailable nociceptin‐1 receptor antagonist reduces ethanol self‐administration and ethanol‐seeking in animal models of alcohol addiction (656.2)

44. A novel N/OFQ antagonist that is potent, selective, orally‐bioavailable, and has demonstrable on‐target actions (656.4)

45. Genetic ablation of myelin protein zero-like 3 in mice increases energy expenditure, improves glycemic control, and reduces hepatic lipid synthesis

46. Development of LC-MS/MS-Based Receptor Occupancy Tracers and Positron Emission Tomography Radioligands for the Nociceptin/Orphanin FQ (NOP) Receptor

49. Discovery of Aminobenzyloxyarylamides as κ Opioid Receptor Selective Antagonists: Application to Preclinical Development of a κ Opioid Receptor Antagonist Receptor Occupancy Tracer

50. Synthesis and Evaluation of Radioligands for Imaging Brain Nociceptin/Orphanin FQ Peptide (NOP) Receptors with Positron Emission Tomography

Catalog

Books, media, physical & digital resources